uniQure N.V. (QURE)
NASDAQ: QURE · IEX Real-Time Price · USD
4.690
+0.010 (0.21%)
At close: May 3, 2024, 4:00 PM
4.680
-0.010 (-0.21%)
After-hours: May 3, 2024, 4:00 PM EDT
uniQure Revenue
In the year 2023, uniQure had annual revenue of $15.84M, a decrease of -85.12%. Revenue in the quarter ending December 31, 2023 was $6.69M, a -93.49% decrease year-over-year.
Revenue (ttm)
$15.84M
Revenue Growth
-85.12%
P/S Ratio
14.37
Revenue / Employee
$33,006
Employees
480
Market Cap
227.65M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 15.84M | -90.64M | -85.12% |
Dec 31, 2022 | 106.48M | -417.52M | -79.68% |
Dec 31, 2021 | 524.00M | 486.49M | 1,296.82% |
Dec 31, 2020 | 37.51M | 30.23M | 415.23% |
Dec 31, 2019 | 7.28M | -4.00M | -35.48% |
Dec 31, 2018 | 11.28M | -1.82M | -13.91% |
Dec 31, 2017 | 13.11M | -11.99M | -47.78% |
Dec 31, 2016 | 25.10M | 14.52M | 137.27% |
Dec 31, 2015 | 10.58M | 4.44M | 72.25% |
Dec 31, 2014 | 6.14M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionQURE News
- 2 months ago - uniQure Announces 2023 Financial Results and Highlights Recent Company Progress - GlobeNewsWire
- 4 months ago - uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington's Disease - GlobeNewsWire
- 5 months ago - CSL Behring's HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates at Three Years Post-Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia B - PRNewsWire
- 5 months ago - uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 months ago - uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-191 Gene Therapy for Fabry Disease - GlobeNewsWire
- 6 months ago - uniQure Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress - GlobeNewsWire
- 6 months ago - CSL and uniQure Win 2023 Prix Galien USA Award - PRNewsWire
- 6 months ago - uniQure Announces Major Presence at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting - GlobeNewsWire